01409nas a2200505   4500000000100000000000100001000000100002008004100003653001000044653001600054653000900070653004300079653004600122653007100168653001100239653001100250653005700261653000900318653001600327653002100343653003200364653002600396653001700422653001600439653007700455653001600532100001400548700001100562700001500573700002000588700001200608700001600620700001600636700001000652700002300662700001400685700001400699700001300713700001400726245011400740250001500854300001200869490000800881020001400889       2020                            d10aAdult10aAge Factors10aAged10aDiabetes Mellitus, Type 2/drug therapy10aDiabetic Ketoacidosis/*chemically induced10aDipeptidyl-Peptidase IV Inhibitors/adverse effects/therapeutic use10aFemale10aHumans10aHypoglycemic Agents/*adverse effects/therapeutic use10aMale10aMiddle Aged10apropensity score10aProportional Hazards Models10aRetrospective Studies10aRisk Factors10aSex Factors10aSodium-Glucose Transporter 2 Inhibitors/*adverse effects/therapeutic use10aYoung Adult1 aA. Douros1 aL. Lix1 aM. Fralick1 aS. Dell'Aniello1 aB. Shah1 aP. Ronksley1 aÉ Tremblay1 aN. Hu1 aS. Alessi-Severini1 aA. Fisher1 aS. Bugden1 aP. Ernst1 aK. Filion00aSodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study  a2020/07/28  a417-4250 v173  a0003-4819